Recombinant Zoster Vaccine Reduces All‐Cause Mortality, But Not Major Adverse Cardiovascular Events, in Patients With Immune‐Mediated Inflammatory Diseases Receiving Janus Kinase Inhibitors: A Large‐Scale Real‐World Retrospective Cohort Study

Documenti analoghi

• Methodological Considerations in Evaluating Recombinant Zoster Vaccine Effectiveness in COPD Patients
  di: Bor‐Yun Wang, et al.
  Pubblicazione: (2025)
• Comment on Limitations of “Assessing Herpes Zoster Vaccine Efficacy in Patients With Diabetes: A Community‐Based Cohort Study”
  di: Rachel A. Cohen, et al.
  Pubblicazione: (2024)
• Epidemiology and Clinical Profile of Herpes Zoster in the Varicella Vaccine Era: A Case Series Study
  di: Binshan Jiang, et al.
  Pubblicazione: (2025)
• Varicella‐Zoster Virus‐Specific Cell‐Mediated Immune Response Kinetics and Latent Viral Load Depending on Aging
  di: Hyo‐Ju Son, et al.
  Pubblicazione: (2025)
• Morbidity and Mortality Among People Living With HTLV‐1: A 30‐Year Retrospective Analysis in a Brazilian Cohort
  di: Elizabeth Souza Neves, et al.
  Pubblicazione: (2026)